Table 4.
Independent predictors for the achievement of LDA at 24 weeks in multivariable analysis
| Tofacitinib | Baricitinib | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Univariate model | Multivariable model | Univariate model | Multivariable model | ||||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Age (per 1-year increase) | 0.997 (0.969–1.026) | 0.838 | – | 0.987 (0.951–1.023) | 0.462 | – | ||
| Disease duration (per 1-year increase) | 0.999 (0.965–1.034) | 0.944 | – | 0.965 (0.919–1.014) | 0.153 | – | ||
| Concomitant MTX use (yes/no) | 1.02 (0.499–2.085) | 0.957 | – | 1.869 (0.770–4.535) | 0.165 | – | ||
| Concomitant oral steroid use (yes/no) | 0.403 (0.203–0.799) | 0.008* | 0.470 (0.232–0.953) | 0.035* | 0.412 (0.167–1.013) | 0.050 | 0.339 (0.102–1.129) | 0.073 |
| Number of previous use of b/tsDMARDs (per drug) | 0.882 (0.714–1.09) | 0.240 | – | 0.687 (0.522–0.905) | 0.005* | 0.700 (0.504–0.971) | 0.026* | |
| Inadequate response of another JAK inhibitor (yes/no) | 0.511 (0.194–1.341) | 0.167 | – | |||||
| DAS28-ESR at baseline (per 1 increase) | 0.798 (0.628–1.014) | 0.061 | 0.882 (0.678–1.147) | 0.345 | 0.395 (0.247–0.633) | < 0.001* | 0.395 (0.225–0.694) | < 0.001* |
| mHAQ (per 1 increase) | 0.603 (0.366–0.996) | 0.039* | 0.745 (0.424–1.304) | 0.294 | 0.322 (0.155–0.667) | < 0.001* | 0.697 (0.301–1.611) | 0.396 |
| ACPA positive (yes/no) | 1.286 (0.568–2.912) | 0.543 | – | 0.426 (0.138–1.314) | 0.131 | – | ||
| RF positive (yes/no) | 1.687 (0.733–3.886) | 0.207 | – | 0.429 (0.115–1.599) | 0.198 | – | ||
OR odds ratio, 95% CI 95% confidence interval, MTX methotrexate, b/tsDMARDs biological and/or targeted synthetic disease-modifying antirheumatic drugs, JAK Janus kinase, DAS disease activity score, mHAQ modified Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor
*P < 0.05